Gyre Therapeutics (GYRE) Tax Provisions (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Tax Provisions of $621000.0 for Q1 2026, down 31.08% year-over-year from $901000.0 in Q1 2025, and up 377.23% quarter-over-quarter from -$224000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Tax Provisions (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Tax Provisions for 8 consecutive years, with $621000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions fell 31.08% year-over-year to $621000.0; the TTM figure through Mar 2026 stood at $2.8 million (down 25.12% YoY), while the FY2025 annual figure was $3.0 million, down 43.01% from the prior year.
- Tax Provisions rose to $621000.0 in Q1 2026 per GYRE's latest filing, from -$224000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $6.0 million in Q4 2022 and bottomed at -$224000.0 in Q4 2025.
- Historically, Tax Provisions has averaged $1.7 million across 5 years, with a median of $1.3 million in 2024.
- On a YoY basis, Tax Provisions climbed as much as 57.64% in 2025 and fell as far as 210.34% in 2025.
- Gyre Therapeutics' Tax Provisions stood at $6.0 million in 2022, then tumbled by 88.33% to $699000.0 in 2023, then sank by 70.96% to $203000.0 in 2024, then slumped by 210.34% to -$224000.0 in 2025, then jumped by 377.23% to $621000.0 in 2026.
- Business Quant data shows GYRE's Tax Provisions at $621000.0 in Q1 2026, -$224000.0 in Q4 2025, and $1.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | -164,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -164,000.00 |
| Mar 31, 2026 | 621,000.00 |
| Dec 31, 2025 | 2.41 Mn |
| Sep 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 662,000.00 |
| Mar 31, 2025 | 901,000.00 |
| Dec 31, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 2.55 Mn |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 3.68 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Mar 31, 2023 | 2.05 Mn |
| Dec 31, 2022 | 5.99 Mn |
| Mar 31, 2015 | 21,000.00 |
| Dec 31, 2014 | 16,000.00 |
| Sep 30, 2014 | 11,000.00 |
| Jun 30, 2014 | 45,000.00 |
| Mar 31, 2014 | 3.41 Mn |